로그인 회원가입
icon_bulk_order대량 주문 조회 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > PSMA

PSMA

요약

Name:Prostate-Specific Membrane Antigen
Target Synonym:EC:3.4.17.21,GIG27,Glutamate carboxypeptidase II,NAALADase I,FOLH,Cell growth-inhibiting gene 27 protein,PSM,N-acetylated-alpha-linked acidic dipeptidase I,GCPII,Folylpoly-gamma-glutamate carboxypeptidase,Folate hydrolase 1,FOLH1,Pteroylpoly-Gamma-Glutamate Carboxypeptidase,Membrane Glutamate Carboxypeptidase,Glutamate Carboxypeptidase 2,Glutamate Carboxylase II,NAALAD1,FGCP,PSMA,MGCP,Folate Hydrolase (Prostate-Specific Membrane Antigen) 1,N-Acetylated Alpha-Linked Acidic Dipeptidase 1,Prostate
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:43
Lastest Research Phase:Approved

제품 리스트 비교 또는 구매

일부의 생물활성 데이터

PSA-HP2Q3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-PSMA CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human PSMA, His Tag (Cat. No. PSA-HP2Q3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

PSA-H5264-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis of Human PSMA, Fc Tag binding to PSMA-CAR-293 cells transfected with anti-PSMA-scFv 2X105 of PSMA-CAR-293 cells transfected with anti-PSMA-scFv were stained with 100μl of 1μg/mL of Human PSMA, Fc Tag (Cat. No. PSA-H5264) and negative control protein respectively, washed and then followed by PE anti-human IgG Fc antibody and analyzed with FACS (Routinely tested).

PSA-H5264-ELISA
Human PSMA, Fc TagHuman PSMA, Fc Tag (Cat. No. PSA-H5264) ELISA bioactivity

Immobilized Human PSMA, Fc Tag (Cat. No. PSA-H5264) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human PSMA Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (QC tested).

PSA-R5245-MALS-HPLC
Rat PSMA, His Tag (Cat. No. ) MALS images

The purity of Rat PSMA, His Tag (Cat. No. PSA-R5245) is more than 90% and the molecular weight of this protein is around 170-208 kDa verified by SEC-MALS.

Bioactivity

Measured by its ability to hydrolyze the substrate N-acetyl-L-Asp-L-Glu into N-acetyl-L-Asp and L-Glu. The L-Glu product is measured by fluorescence after its derivatization by ortho-phthaldialdehyde. The specific activity is >300 pmol/min/μg, as measured under the described conditions (QC tested).

사용자 리뷰

Synonym Name

FOLH1,PSMA,GIG27,FOLH,NAALAD1,PSM,NAALADase I,GCPII,FGCP

Background

The biotinylated PSMA protein was conjugated to streptavidin magnetic beads. This pre-coupled magnetic bead product can capture the anti-PSMA antibody from various assay systems. The beads are in uniform size, narrow size distribution with large surface area and unique surface coating, which can help you get the best performance and highly reproducible results. This PSMA coupled magnetic beads will bring great convenience with minimum non-specific binding and developed protocols. This ready-to-use product could greatly save your time and hassle.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Lutetium (177Lu) vipivotide tetraxetan Lu-177- RLT; PSMA-617-[177Lu]; Lutetium-177-PSMA-617; 177-Lu-PSMA-617; AAA-617 Approved Radiomedix PLUVICTO United States Prostatic Neoplasms, Castration-Resistant Advanced Accelerator Applications Usa Inc 2022-03-23 Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
Piflufolastat F 18 Approved Johns Hopkins University Pylarify United States Prostatic Neoplasms Progenics Pharmaceuticals Inc 2021-05-26 Carcinoma, Renal Cell; Prostatic Neoplasms Details
Capromab pendetide lndium-CYT-356; Indium-111-CYT-356; CYT-356; 111In CYT-356 Approved Eusa Pharma ProstaScint United States Prostatic Neoplasms Cytogen 1996-10-28 Prostatic Neoplasms Details
Ga-68 PSMA-11 Ga-68-PSMA-11; 68Ga-HBED-CC-PSMA11; Ga-68-PSMA Approved Radiomedix Gallium Ga 68 Psma-11, Illuccix, ILLUCCIX United States Prostatic Neoplasms Telix Pharmaceuticals Ltd, University Of California, San Francisco Foundation 2020-12-01 Solid tumours; Neoplasm Recurrence, Local; Recurrence; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Digestive System Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Neoplasm Metastasis; Carcinoma, Hepatocellular Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
P28z-CAR P28z-CAR Phase 1 Clinical Memorial Sloan Kettering Cancer Center, United States Department Of Defense Prostatic Neoplasms Details
89Zr-DFO-huJ591 Zr89-J591; 89Zr-DFO-J591; 89Zr-DFO-huJ591 Phase 2 Clinical Memorial Sloan Kettering Cancer Center Prostatic Neoplasms Details
Anti-PSMA CAR T-cell therapy (TNK Therapeutics) Phase 1 Clinical Sorrento Therapeutics Neoplasms Details
CART-PSMA-TGFbRDN (University of Pennsylvania) Phase 1 Clinical University Of Pennsylvania Prostatic Neoplasms Details
Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center Phase 1 Clinical Roger Williams Medical Center Prostatic Neoplasms Details
CCW-702 CCW-702 Phase 1 Clinical The Scripps Research Institute, Abbvie Inc Prostatic Neoplasms Details
68Ga-PSMA-R2 (Advanced Accelerator Applications SA) Clinical Advanced Accelerator Applications Sa Prostatic Neoplasms Details
TLX-592 TLX-592 Phase 2 Clinical Telix Pharmaceuticals Ltd Prostatic Neoplasms Details
68Ga-PSMA-IRDye TLX591-Sx Phase 2 Clinical Telix Pharmaceuticals Prostatic Neoplasms Details
177Lu-EB-vipivotide tetraxetan 177-Lu-EB-PSMA-617 Phase 1 Clinical National Institute For Biomedical Imaging And Bioengineering (Nibib), Peking Union Medical College Hospital Carcinoma, Renal Cell; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Adenoid Cystic Details
Lu-177-DGUL Lu-177-DGUL; 177Lu-DOTA-GUL; PSMA-D GUL Phase 2 Clinical Neoplasms Details
CONV-01-alpha + PSMA I&T Phase 2 Clinical Convergent Therapeutics Inc Prostatic Neoplasms Details
GD2/PSMA Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) bi-4SCAR GD2/PSMA Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Solid tumours Details
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell Details
PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) bi-4SCAR PSMA/CD70 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Neoplasms Details
99mTc-EC-0652 EC-0652; DUPA-99mTc; 99mTc-EC-0652; EC-0652-99mTc Novartis Pharma Ag Details
INO-5401 INO-5401 Inovio Details
CBP-1018 CBP-1018 Phase 1 Clinical Coherent Biopharma Suzhou Co Ltd Solid tumours; Carcinoma, Renal Cell; Prostatic Neoplasms; Lung Neoplasms Details
[Lu177]-PNT-2002 PNT-2002 Phase 2 Clinical Point Biopharma Inc Prostatic Neoplasms Details
INO-5150 INO-5150 Inovio Details
ARX-517 ARX-517 Phase 1 Clinical Ambrx Inc Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
67Cu-SAR-bisPSMA (Clarity Pharmaceuticals) Details
64Cu-SAR-bisPSMA (Clarity Pharmaceuticals) Details
TNB-585 AMG-340; TNB-585 Phase 1 Clinical Teneobio, Amgen Inc Prostatic Neoplasms, Castration-Resistant Details
REGN-4336 REGN-4336 Regeneron Pharmaceuticals Inc Details
123-I-MIP-1095 123-I-MIP-1095 Molecular Insight Pharmaceuticals Inc Details
123I-MIP-1072 123-I-MIP-1072 Molecular Insight Pharmaceuticals Inc Details
4SCAR-PSMA T cell therapy (Shenzhen Geno-Immune Medical Institute) Shenzhen Geno-Immune Medical Institute Details
Fluorine-18-CTT-1057 CTT-1057; 18F-CTT1057; CTT-1057-18F; CTT-1057-F-18 Washington University, Cancer Targeted Technology Details
[131I]MIP-1095 1095; [131I]MIP-1095; [131I]MIP-1466 Progenics Pharmaceuticals Inc Details
[177Lu]-CTT-1403 CTT-1403; [177Lu]CTT1403; 177Lutetium CTT1403; [177Lu]CTT-1403 Cancer Targeted Technology Details
Acapatamab AMG-160 Phase 1 Clinical Amgen Inc Prostatic Neoplasms, Castration-Resistant Details
HPN-424 HPN-424 Harpoon Therapeutics Details
Pasotuxizumab BAY-2010112; AMG-212; MT-112 Amgen Inc Details
PSMA-CART cell therapy (Shanghai Bioray Laboratory) Bioray Laboraytories Inc Details
CYT-500-Lu-177 177LuCYT500; CYT-500-Lu-177 Cytogen Details
MOR-209/ES414 APVO-414; MOR-209; ES-414 Emergent Details
225Ac-J591 225Ac-DOTA-J591; 225Ac-J591; CONV 01-α Phase 2 Clinical Cornell University Prostatic Neoplasms Details
JNJ-63898081 JNJ-8081; JNJ-63898081 Janssen Global Services Llc Details
REGN-5678 REGN-5678 Regeneron Pharmaceuticals Inc Details
PSMA ADC PSMA-ADC Progenics Pharmaceuticals Inc, Psma Development Company Details
225 Actinium PSMA 617 (Novartis) 225 Actinium PSMA-617; 225Ac-PSMA 617; AAA 817; 225Ac-PSMA-617 Phase 1 Clinical Novartis Pharma Ag, Endocyte Inc, Advanced Accelerator Applications Sa Prostatic Neoplasms, Castration-Resistant Details
Df-IA2BM-Zr-89 Df-IA2BM-Zr-89; 89Zr-Df-IAB2M; IAB2M Imaginab Inc Details
177Lu-PSMA-R2 177Lu-PSMA-R2; 177Lu-PSMA-SR6; AAA-602 Phase 2 Clinical Advanced Accelerator Applications Sa Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
JNJ-80038114 JNJ-80038114 Phase 1 Clinical Janssen Research & Development Llc Prostatic Neoplasms Details
Pelgifatamab corixetan BAY-2315497 Phase 1 Clinical Bayer AG Prostatic Neoplasms Details
CC-1 CC-1 Phase 2 Clinical The University Of Tubingen, Deutsches Krebsforschungszentrum, Dkfz Prostatic Neoplasms, Castration-Resistant; Carcinoma, Squamous Cell Details
LAVA-1207 LAVA-1207 Phase 2 Clinical Vu University Medical Center Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
Gallium-68 PSMA-617 225 Ac-PSMA-617; 68Ga-PSMA-617; 68Ga-DKFZ-617; 68Ga-DKFZ-PSMA -617; 68Ga-DOTA-PSMA-DKFZ -617; Gallium-68-PSMA-617; PSMA-617-[68Ga] Phase 1 Clinical Peking Union Medical College Hospital Prostatic Neoplasms Details
177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1; (177Lu) rhPSMA-10.1 Phase 2 Clinical Blue Earth Therapeutics Ltd Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Urogenital Neoplasms; Prostatic Diseases Details
177Lu-DOTA-rosopatamb TLX591; 177Lu-DOTA-TLX591-CHO Phase 3 Clinical Telix Pharmaceuticals Ltd Prostatic Neoplasms Details
ATL-101 MLN-591RL; ATL-101; huJ-591; MLN-591; J-591; Lu-177-J591; 177Lu-J591; 90Y-J591; muJ-591 Phase 1 Clinical Weill Medical College of Cornell University Prostatic Neoplasms Details

This web search service is supported by Google Inc.

totop